Franklin Street Advisors Inc. NC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.7% in the 4th quarter, Holdings Channel reports. The firm owned 46,720 shares of the company’s stock after acquiring an additional 3,730 shares during the period. Franklin Street Advisors Inc. NC’s holdings in IDEXX Laboratories were worth $7,306,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of IDXX. D.A. Davidson & CO. raised its holdings in shares of IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares during the last quarter. Sun Life Financial INC raised its holdings in shares of IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares during the last quarter. BB&T Investment Services Inc. acquired a new position in shares of IDEXX Laboratories in the second quarter worth $104,000. Zions Bancorporation acquired a new position in shares of IDEXX Laboratories in the third quarter worth $162,000. Finally, Coastline Trust Co acquired a new position in shares of IDEXX Laboratories in the second quarter worth $202,000. 86.61% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the completion of the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,529,058.53. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,000 shares of company stock valued at $16,686,200. Company insiders own 2.77% of the company’s stock.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. research analysts forecast that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.
A number of research firms have recently weighed in on IDXX. BidaskClub raised IDEXX Laboratories from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a report on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. IDEXX Laboratories presently has a consensus rating of “Hold” and an average price target of $173.67.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.